Nexalin Technology (NXL) said Tuesday that the University of California in San Diego Institutional Review Board has approved the use of its Halo Clarity headset in human subjects in clinical trials.
The headsets will be tested in clinical trials to assess their efficacy in treating mild traumatic brain injury and post-traumatic stress disorder, particularly in military personnel, the company said.
The company and its manufacturing partner have begun preparing the initial shipment of 50 headsets to the university, which is conducting the study independently, Nexalin said.
Nexalin said the headset is a non-invasive treatment that can be used at home and allows physicians to monitor patient progress remotely.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。